Stem cell platforms for regenerative medicine

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The pandemic of chronic degenerative diseases associated with aging demographics mandates development of effective approaches for tissue repair. As diverse stem cells directly contribute to innate healing, the capacity for de novo tissue reconstruction harbors a promising role for regenerative medicine. Indeed, a spectrum of natural stem cell sources ranging from embryonic to adult progenitors has been recently identified with unique characteristics for regeneration. The accessibility and applicability of the regenerative armamentarium has been further expanded with stem cells engineered by nuclear reprogramming. Through strategies of replacement to implant functional tissues, regeneration to transplant progenitor cells or rejuvenation to activate endogenous self-repair mechanisms, the overarching goal of regenerative medicine is to translate stem cell platforms into practice and achieve cures for diseases limited to palliative interventions. Harnessing the full potential of each platform will optimize matching stem cell-based biologics with the disease-specific niche environment of individual patients to maximize the quality of long-term management, while minimizing the needs for adjunctive therapy. Emerging discovery science with feedback from clinical translation is therefore poised to transform medicine offering safe and effective stem cell biotherapeutics to enable personalized solutions for incurable diseases.

Original languageEnglish (US)
Pages (from-to)222-227
Number of pages6
JournalClinical and Translational Science
Volume2
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Regenerative Medicine
Stem cells
Stem Cells
Repair
Regeneration
Tissue
Tissue regeneration
Transplants
Rejuvenation
Ports and harbors
Biological Products
Population Dynamics
Pandemics
Medicine
Aging of materials
Chronic Disease
Feedback

Keywords

  • Adult
  • Allogeneic
  • Autologous
  • Bioengineered
  • Embryonic
  • Immune response
  • Perinatal

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Stem cell platforms for regenerative medicine. / Nelson, Timothy J; Behfar, Atta; Yamada, Satsuki; Martinez-Fernandez, Almudena; Terzic, Andre.

In: Clinical and Translational Science, Vol. 2, No. 3, 2009, p. 222-227.

Research output: Contribution to journalArticle

@article{1efe5dc33e0f493e92b54057da38e457,
title = "Stem cell platforms for regenerative medicine",
abstract = "The pandemic of chronic degenerative diseases associated with aging demographics mandates development of effective approaches for tissue repair. As diverse stem cells directly contribute to innate healing, the capacity for de novo tissue reconstruction harbors a promising role for regenerative medicine. Indeed, a spectrum of natural stem cell sources ranging from embryonic to adult progenitors has been recently identified with unique characteristics for regeneration. The accessibility and applicability of the regenerative armamentarium has been further expanded with stem cells engineered by nuclear reprogramming. Through strategies of replacement to implant functional tissues, regeneration to transplant progenitor cells or rejuvenation to activate endogenous self-repair mechanisms, the overarching goal of regenerative medicine is to translate stem cell platforms into practice and achieve cures for diseases limited to palliative interventions. Harnessing the full potential of each platform will optimize matching stem cell-based biologics with the disease-specific niche environment of individual patients to maximize the quality of long-term management, while minimizing the needs for adjunctive therapy. Emerging discovery science with feedback from clinical translation is therefore poised to transform medicine offering safe and effective stem cell biotherapeutics to enable personalized solutions for incurable diseases.",
keywords = "Adult, Allogeneic, Autologous, Bioengineered, Embryonic, Immune response, Perinatal",
author = "Nelson, {Timothy J} and Atta Behfar and Satsuki Yamada and Almudena Martinez-Fernandez and Andre Terzic",
year = "2009",
doi = "10.1111/j.1752-8062.2009.00096.x",
language = "English (US)",
volume = "2",
pages = "222--227",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Stem cell platforms for regenerative medicine

AU - Nelson, Timothy J

AU - Behfar, Atta

AU - Yamada, Satsuki

AU - Martinez-Fernandez, Almudena

AU - Terzic, Andre

PY - 2009

Y1 - 2009

N2 - The pandemic of chronic degenerative diseases associated with aging demographics mandates development of effective approaches for tissue repair. As diverse stem cells directly contribute to innate healing, the capacity for de novo tissue reconstruction harbors a promising role for regenerative medicine. Indeed, a spectrum of natural stem cell sources ranging from embryonic to adult progenitors has been recently identified with unique characteristics for regeneration. The accessibility and applicability of the regenerative armamentarium has been further expanded with stem cells engineered by nuclear reprogramming. Through strategies of replacement to implant functional tissues, regeneration to transplant progenitor cells or rejuvenation to activate endogenous self-repair mechanisms, the overarching goal of regenerative medicine is to translate stem cell platforms into practice and achieve cures for diseases limited to palliative interventions. Harnessing the full potential of each platform will optimize matching stem cell-based biologics with the disease-specific niche environment of individual patients to maximize the quality of long-term management, while minimizing the needs for adjunctive therapy. Emerging discovery science with feedback from clinical translation is therefore poised to transform medicine offering safe and effective stem cell biotherapeutics to enable personalized solutions for incurable diseases.

AB - The pandemic of chronic degenerative diseases associated with aging demographics mandates development of effective approaches for tissue repair. As diverse stem cells directly contribute to innate healing, the capacity for de novo tissue reconstruction harbors a promising role for regenerative medicine. Indeed, a spectrum of natural stem cell sources ranging from embryonic to adult progenitors has been recently identified with unique characteristics for regeneration. The accessibility and applicability of the regenerative armamentarium has been further expanded with stem cells engineered by nuclear reprogramming. Through strategies of replacement to implant functional tissues, regeneration to transplant progenitor cells or rejuvenation to activate endogenous self-repair mechanisms, the overarching goal of regenerative medicine is to translate stem cell platforms into practice and achieve cures for diseases limited to palliative interventions. Harnessing the full potential of each platform will optimize matching stem cell-based biologics with the disease-specific niche environment of individual patients to maximize the quality of long-term management, while minimizing the needs for adjunctive therapy. Emerging discovery science with feedback from clinical translation is therefore poised to transform medicine offering safe and effective stem cell biotherapeutics to enable personalized solutions for incurable diseases.

KW - Adult

KW - Allogeneic

KW - Autologous

KW - Bioengineered

KW - Embryonic

KW - Immune response

KW - Perinatal

UR - http://www.scopus.com/inward/record.url?scp=75949106265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75949106265&partnerID=8YFLogxK

U2 - 10.1111/j.1752-8062.2009.00096.x

DO - 10.1111/j.1752-8062.2009.00096.x

M3 - Article

C2 - 19779576

AN - SCOPUS:75949106265

VL - 2

SP - 222

EP - 227

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 3

ER -